Download Poster (1.2 MB)
• Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the US.
• PDA is resistant to conventional chemotherapy; however, mechanisms that contribute to this chemoresistance are not well-described.
• The tumor microenvironment in PDA has a dense stromal reaction, which is thought to result in low oxygen and low nutrient conditions (Feig, C., et al. 2012).
• Isocitrate Dehydrogenase 1 (IDH1) has been identified as an enzyme that plays an important role in chemoresistance in PDA (Zarei, M., et al. In progress).
• We sought to establish an IDH1 knockout cell line to further study its role in PDA using the CRISPR-Cas9 targeted genome editing system.
Generation of CRISPR knockout of IDH1 in pancreatic ductal adenocarcinoma cell line: An optimal model to study pancreatic cancer metabolic reprogramming, Department of Surgery, Thomas Jefferson University
Medicine and Health Sciences | Surgery
Dukleska, MD, Katerina; Zarei, PhD, Mahsa; Vaziri-Gohar, PhD, Ali; Yeo, MD, Charles J.; Brody, MD, Jonathan; and Winter, MD, Jordan M., "Generation of CRISPR knockout of IDH1 in pancreatic ductal adenocarcinoma cell line: An optimal model to study pancreatic cancer metabolic reprogramming" (2017). Department of Surgery Posters. 8.